How We WorkOrder NowSupport Privacy

Biotech Stocks in Focus – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Sarepta Therapeutics Inc (NASDAQ:SRPT)

on 28/03/2013

New York, NY – (Net PR News) – 3/28/2013–smartOTC is the premiere destination for Investors and novices alike who wish to receive information on fast moving OTC stocks and undiscovered companies. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.

Sign up For Our No. 1 Rated Stock Newsletter to make Huge Profitshttp://www.smartotc.com

The Healthcare Sector of the Biotechnology Industry stocks are in focus, as its stocks were gaining high volume during previous trade. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) remained with higher volume in its industry and showing a positive trend during the previous trading session and Sarepta Therapeutics Inc (NASDAQ:SRPT) was in focus of investors and it was showing bullish movement during previous trade.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) revealed that, from Saturday, 6th April, 2013 to Wednesday, 10th April, 2013, the company has plans of preclinical data presentations to be made at the American Association for Cancer Research (AACR) 2013 Annual Meeting, in Washington.

How Should Investors Trade ARIA Now? Don’t Miss out a Special Trend Analysis

Healthcare sector stock, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), reported the upsurge of 1.33% and closed at $18.31 with the total traded volume of 2,730,400 shares. The stock’s opening price was $18.03. The company has a total of 166.66 million outstanding shares and its total market capitalization is $3.05 billion.

The 52-week price range of the stock remained $14.10 – $25.40, while during last trade its minimum price was $17.88 and it gained its highest price of $18.44. Company’s last 5 days shows a downtrend with the drop of -16.05%.

Can Investors Bet on ARIA after this News update? Find out in this Research Report

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced its operating loss remained $10.4 million for the 4th Q of 2012, in comparison to the last year same period of $9.0 million. The operating loss for the year 2012 reported $29.7 million, versus the year ago of $35.9 million.

Is SRPT a Solid Investment at These Levels? Read This Report For Details

Biotechnology company showing positive momentum during previous trade, Sarepta Therapeutics Inc (NASDAQ:SRPT) reported the upsurge of 0.42% after opening at the price of $35.80. Its closing price for the day was $36.27.

SRPT’s total trading volume for the day was 1,506,400 million shares, versus its average volume of 1.64 million shares. Company’s current market capitalization stands at $1.15 billion along with 31.83 million shares. Sarepta Therapeutics’ earnings per share is $-4.96. If we look at the previous 5 day’s performance of the stock, it remained optimistic with the gain of 12.47%. In its last one month’s trade it jumped 23.81%.

Can SRPT  Show a Strong Recovery? Find out in This Research Report

About Us:

smartOTC is the premiere destination for Investors and novice alike who wish to receive information on fast moving OTC penny stocks and undiscovered companies. We are a marketing firm that releases paid reports on undiscovered companies looking to tell their stories. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.

While penny stocks pose a much more significant risk factor compared to large cap stocks, their lure of quick gains makes it a trading choice for many small time and beginner investors. There is nothing wrong with investments into penny stocks, the best advice is to do your own research and consult with your own financial professional. smartOTC reports and alerts should only be used as a starting point for your own due diligence.

Disclaimer:

PLEASE NOTE WELL: This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation.

Smartotc.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The disclaimer is to be read and fully understood before using our site, or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Read Our Full Disclaimer at http://www.smartotc.com/disclaimer

Source: smartotc Posted Thu, March 28, 2013 12:53 - Permalink